A physician is attempting new therapies for HIV patients who are suffering from an impaired immune response. He decides to try using a recombinant form of colony-stimulating factor cytokine (CSF). Why?

A. CSF is a strong inducer of antiviral activities in our cells, and may help our immune system fight off the effects of HIV for a longer period of time.
B. CSF will hyperstimulate the activities of the macrophages, leading to ingestion and destruction of HIV-infected cells.
C.
CSF will help to stimulate the production of new lymphocytes-the very cells that are infected and depleted during an HIV infection. This may help to keep the patients' immune responses "normal" for a longer period of time before they succumb to full-blown AIDS.

D. CSF will drive up the production of lactoferrin, a strong antiviral compound produced in our mucus membrane secretions.


C

Biology & Microbiology

You might also like to view...

Which disease involves transmission by aerosolized water from whirlpool spas, air conditioners, cooling towers, and supermarket vegetable misters?

A. Pertussis B. Legionellosis C. Brucellosis D. Traveler's diarrhea E. Plague

Biology & Microbiology

Which of these human characteristics is hypothesized to have evolved first?

A) enlarged brain B) erect posture C) language D) loss of body hair

Biology & Microbiology

What are the two major methods of cellular division in eukaryotic cells?

a. fission and cloning b. mitosis and cloning c. meiosis and fission d. meiosis and mitosis e. meiosis and cloning

Biology & Microbiology

How does inhibition of an enzyme-catalyzed reaction by a competitive inhibitor differ from inhibition by a noncompetitive inhibitor?

A) Competitive inhibitors interfere with the enzyme; noncompetitive inhibitors interfere with the reactants. B) Competitive inhibitors bind to the enzyme reversibly; noncompetitive inhibitors bind to it irreversibly. C) Competitive inhibitors change the enzyme's tertiary structure; noncompetitive inhibitors cause polypeptide subunits to dissociate. D) Competitive inhibitors bind to the active site of the enzyme; noncompetitive inhibitors bind to a different site.

Biology & Microbiology